Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pleomorphic Xanthoastrocytoma: early-phase trial registry
2 of 4 indexed Pleomorphic Xanthoastrocytoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Pleomorphic Xanthoastrocytoma: 4 US clinical trials tracked, 2 recruiting.
Pleomorphic Xanthoastrocytoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Julie Krystal, running 1 of these trials.
Enrollment posture brief
Registry condition pleomorphic-xanthoastrocytoma
OPEN 2 | RECR 50% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Pleomorphic Xanthoastrocytoma lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pleomorphic Xanthoastrocytoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pleomorphic Xanthoastrocytoma is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT04541082
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
St. Jude Children's Research Hospital
NCT04065776
Pediatric Long-Term Follow-up and Rollover Study
Novartis Pharmaceuticals
NCT03975829
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Julie Krystal
NCT01837862
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pleomorphic Xanthoastrocytoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pleomorphic Xanthoastrocytoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pleomorphic Xanthoastrocytoma page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Pleomorphic Xanthoastrocytoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Julie Krystal sponsors the most Pleomorphic Xanthoastrocytoma trials on record, review their full trial history before evaluating a specific study. See Julie Krystal's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pleomorphic Xanthoastrocytoma condition card totals 4 registered trials; most-linked intervention Mebendazole; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.